Long-term safety of first-line osimertinib plus platinum–pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2

Study limitation reported by the research below: “Sample size tagged as n=276 (induction period); numbers shift across treatment periods (201 and 206), so the single sample size tag may not reflect all analyses.”